InterMune is dedicated to the clearer understanding of IPF and is working toward advancing care for patients with idiopathic pulmonary fibrosis (IPF). This is a serious condition that affects approximately 80,000 adults in the United States and more than 60,000 adults in Europe.

Both CAPACITY trials will assess the safety and efficacy of pirfenidone and placebo treatment in patients with IPF.

Two phase 3, randomized, double-blind, placebo-controlled safety and efficacy studies in patients with IPF.

• Approximately 720 patients will be enrolled at centers around the world
• Patients are randomly assigned to receive either Pirfenidone or placebo

Primary: Change in percent predicted FVC from baseline to week 72.
Secondary: Changes in lung function, symptoms, functional status, and quality of life.

If you need further information regarding these trials please submit a Medical Information Request Form or call our Medical Information Department toll-free number at 1-888-ITMN-411 (1-888-486-6411).